Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Clinect Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to establish a national system for regulating therapeutic goods in Australia, addressing the need for a cohesive regulatory framework governing the quality, safety, efficacy, and timely availability of such goods. The Act empowers the Therapeutic Goods Administration (TGA) within the Department of Health to implement and enforce the legislative provisions aimed at protecting public health by ensuring that therapeutic goods meet the necessary standards. In the case of Clinect Pty Ltd, a consent was granted under sections 14 and 14A of the Act to import and supply naproxen sustained release tablets with labels that do not conform to the current labelling requirements, reflecting the need for flexibility in exceptional circumstances to ensure the availability of necessary therapeutic goods while maintaining a balance between regulatory compliance and public health needs. The consent granted is effective for a limited period and is subject to specific conditions designed to mitigate any potential risks associated with the non-conforming labels.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia's Department of Health, governs the regulation of therapeutic goods in Australia. This Act applies to the importation, supply, and manufacturing of therapeutic goods, including medicines, medical devices, and blood and blood components, within the national jurisdiction. Section 14 and 14A of the Act permit specific exceptions to certain regulatory requirements, contingent upon consent from a delegate of the Secretary of the Department of Health. In the context of the notice issued on 25 August 2015, Clinect Pty Ltd received consent to import and supply naproxen sustained release tablets with labels that do not conform to specific labelling requirements, provided that the labels are those previously approved for the former sponsor, Roche Products Pty Ltd, and that certain conditions are met, such as the use of child-resistant closures and redirecting queries to the current sponsor, Atnahs Pharma Australia Pty Ltd. This consent is effective for a limited period, until 31 March 2016, and does not alter the overarching regulatory framework established by the Therapeutic Goods Act 1989.

Key Provisions

Under sections 14 and 14A of the Therapeutic Goods Act 1989, a consent was granted by a delegate of the Secretary of the Department of Health, based on an application from Clinect Pty Ltd, to import and supply specific naproxen products that do not meet the labelling requirements outlined in the Therapeutic Goods Order No. 69. The consent allows for the continued supply of naproxen (PROXEN SR 750) and naproxen (PROXEN SR 1000) sustained release tablets, which bear labels featuring the former supplier's name, logo, and contact details instead of the current sponsor's information. This consent is effective from 25 August 2015 until 31 March 2016 and comes with certain conditions to ensure the safety and proper handling of these products. The Therapeutic Goods Act 1989 imposes several obligations on the entities involved in the importation and supply of therapeutic goods. Firstly, Clinect Pty Ltd must ensure that the labels used for the naproxen products are those previously approved for Roche Products Pty Ltd, the former sponsor. Secondly, there must be clear arrangements for directing all inquiries to Atnahs Pharma Australia Pty Ltd, the current sponsor. Thirdly, the bottles of the naproxen products must be recapped with child-resistant closures as specified in the request dated 18 August 2015 and approved separately. The Act also ensures that no other changes are made to the products apart from the aforementioned labelling and capping modifications. Failure to comply with the conditions outlined in the consent or the requirements of the Therapeutic Goods Act 1989 may result in various legal consequences. Offences under the Act can lead to criminal and/or civil penalties. While the specific penalties are not detailed in the provided text, they typically include fines and potential imprisonment for criminal offences. For civil penalties, the Act may impose monetary penalties, which can vary depending on the severity and nature of the breach. It is essential for Clinect Pty Ltd and all other parties involved to adhere to the Act's provisions to avoid any legal repercussions.